SEC Form 4 · accession 0000899243-17-012361
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
M Scot Roberts
Officer — Chief Scientific Officer
Period of report
May 4, 2017
Accepted (ET)
May 8, 2017 · 8:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (option to buy)F1 | $0.08 | May 4, 2017 | A | 55,120 | A | May 4, 2017 | Dec 5, 2022 | Common Stock, par value $0.0001 | 55,120 | 55,120 | D |
| Stock Option (option to buy)F1,F2 | $0.59 | May 4, 2017 | A | 8,956 | A | — | Dec 4, 2023 | Common Stock, par value $0.0001 | 8,956 | 8,956 | D |
| Stock Option (option to buy)F1,F3 | $2.59 | May 4, 2017 | A | 8,956 | A | — | Dec 2, 2024 | Common Stock, par value $0.0001 | 8,956 | 8,956 | D |
| Stock Option (option to buy)F1,F4 | $13.38 | May 4, 2017 | A | 11,235 | A | — | Apr 7, 2026 | Common Stock, par value $0.0001 | 11,235 | 11,235 | D |
Explanation of responses
- F1Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
- F2The option is currently exercisable to purchase 6,716 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The remaining portion of the option will vest on 12/4/2017.
- F3The option is currently exercisable to purchase 4,477 shares of Common Stock. An additional 25% of the option will vest on each of 12/3/2017 and 12/3/2018.
- F4The option is currently exercisable to purchase 2,809 shares of Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020.